Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mohamad Moussa, Athanasios Papatsoris, Athanasios Dellis, Mohamed Abou Chakra & Charalampos Fragkoulis. (2021) Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy 22:17, pages 2373-2381.
Read now
Read now
Charalampos Fragkoulis, Ioannis Glykas, Athanasios Dellis, Iraklis Mitsogiannis & Athanasios Papatsoris. (2021) Relugolix: A new kid on the block among gonadotrophin-releasing hormone antagonists. Arab Journal of Urology 19:4, pages 460-463.
Read now
Read now
Yuki Kato, Kazuyoshi Shigehara, Shohei Kawaguchi, Kouji Izumi, Yoshifumi Kadono & Atsushi Mizokami. (2020) Recovery of serum testosterone following neoadjuvant androgen deprivation therapy in Japanese prostate cancer patients treated with low-dose rate brachytherapy. The Aging Male 23:5, pages 1210-1216.
Read now
Read now
Athanasios Dellis & Athanasios Papatsoris. (2017) Therapeutic outcomes of the LHRH antagonists. Expert Review of Pharmacoeconomics & Outcomes Research 17:5, pages 481-488.
Read now
Read now
Articles from other publishers (24)
Lei Wang, Nanxi Wang, Zhibin Yan, Zhifeng Huang & Caiyun Fu. 2023. Privileged Scaffolds in Drug Discovery. Privileged Scaffolds in Drug Discovery
795
815
.
Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer
161
204
.
Fangxia Zou, Yao Wang, Dawei Yu, Chunjiao Liu, Jing Lu, Min Zhao, Mingxu Ma, Wenyan Wang, Wanglin Jiang, Yonglin Gao, Rui Zhang, Jianzhao Zhang, Liang Ye & Jingwei Tian. (2022) Discovery of the thieno[2,3-d]pyrimidine-2,4-dione derivative 21a: A potent and orally bioavailable gonadotropin-releasing hormone receptor antagonist. European Journal of Medicinal Chemistry 242, pages 114679.
Crossref
Crossref
Ioanna Mourkioti, Andriani Angelopoulou, Konstantinos Belogiannis, Nefeli Lagopati, Spyridon Potamianos, Efthymios Kyrodimos, Vassilis Gorgoulis & Angelos Papaspyropoulos. (2022) Interplay of Developmental Hippo–Notch Signaling Pathways with the DNA Damage Response in Prostate Cancer. Cells 11:15, pages 2449.
Crossref
Crossref
Sheng Li, Milena Schönke, Jacobus C. Buurstede, Tijmen J.A. Moll, Max Gentenaar, Maaike Schilperoort, Jenny A. Visser, Kasiphak Kaikaew, Davy van de Vijver, Tooba Abbassi-Daloii, Vered Raz, Annemieke Aartsma-Rus, Maaike van Putten, Onno C. Meijer & Jan Kroon. (2022) Sexual Dimorphism in Transcriptional and Functional Glucocorticoid Effects on Mouse Skeletal Muscle. Frontiers in Endocrinology 13.
Crossref
Crossref
Chirag Desai, Ashok K. Vaid, Ghanashyam Biswas, Sandeep Batra, Palanki S. Dattatreya, Prabrajya Narayan Mohapatra, Deepak Dabkara, Adwaita Gore, Sagar B. Bhagat, Saiprasad Patil & Hanmant Barkate. (2022) Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus. Oncology and Therapy 10:1, pages 143-165.
Crossref
Crossref
Daniela Mateus, Ana Isabel Sebastião, Mylène A. Carrascal, Anália do Carmo, Ana Miguel Matos & Maria Teresa Cruz. (2021) Crosstalk between estrogen, dendritic cells, and SARS‐CoV‐2 infection. Reviews in Medical Virology 32:3.
Crossref
Crossref
Hiroshi Sasaki, Kenta Miki, Kojiro Tashiro, Keiichiro Mori, Fumihiko Urabe, Wataru Fukuokaya, Takahiro Kimura, Shun Sato, Hiroyuki Takahashi, Manabu Aoki & Shin Egawa. (2021) Differences in sex hormone recovery profile after cessation of 12‐week gonadotropin‐releasing hormone antagonist versus agonist therapy. Andrology 10:2, pages 270-278.
Crossref
Crossref
Ankur Bahl, Senthil Rajappa, Sudhir Rawal, Ganesh Bakshi, Vedang Murthy & Ketaki Patil. (2022) A review of clinical evidence to assess differences in efficacy and safety of luteinizing hormone–releasing hormone (LHRH) agonist (goserelin) and LHRH antagonist (degarelix). Indian Journal of Cancer 59:5, pages 160.
Crossref
Crossref
Lalanthica V. Yogendran, Marc S. Ernstoff & Camilo E. Fadul. 2022. Neurological Complications of Systemic Cancer and Antineoplastic Therapy. Neurological Complications of Systemic Cancer and Antineoplastic Therapy
387
400
.
Alexander M. Kotlyar, Lubna Pal & Hugh S. Taylor. (2021) Eliminating Hormones With Orally Active Gonadotropin-releasing Hormone Antagonists. Clinical Obstetrics & Gynecology 64:4, pages 837-849.
Crossref
Crossref
Maria Yu Konoshenko, Olga E. Bryzgunova & Pavel P. Laktionov. (2021) miRNAs and androgen deprivation therapy for prostate cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876:2, pages 188625.
Crossref
Crossref
Fabrizio Fontana & Patrizia Limonta. (2021) Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer. Cells 10:5, pages 1133.
Crossref
Crossref
Donald J. AbrahamMichael L. Mohler & James T. Dalton. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
103
.
Ivan Guryanov, Andrea Orlandin, Angelo Viola, Barbara Biondi, Fernando Formaggio, Antonio Ricci & Walter Cabri. (2020) Overcoming Chemical Challenges in the Solid-Phase Synthesis of High-Purity GnRH Antagonist Degarelix. Part 2. Organic Process Research & Development 24:2, pages 274-278.
Crossref
Crossref
Ivan Guryanov, Andrea Orlandin, Angelo Viola, Barbara Biondi, Denis Badocco, Fernando Formaggio, Antonio Ricci & Walter Cabri. (2019) Overcoming Chemical Challenges in the Solid-Phase Synthesis of High-Purity GnRH Antagonist Degarelix. Part 1.. Organic Process Research & Development 23:12, pages 2746-2753.
Crossref
Crossref
P. Hammerer & L. Manka. (2019) Einsatz von Docetaxel oder Abirateron in Kombination mit einer Androgendeprivationstherapie beim metastasierten hormonnaiven ProstatakarzinomDocetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer. Der Urologe 58:10, pages 1185-1197.
Crossref
Crossref
Rumiko Sugimura, Takashi Kawahara, Yasuhide Miyoshi, Masahiro Yao, Sawako Chiba & Hiroji Uemura. (2019) A Case of Switching from GnRH Agonist to Antagonist for Castration Resistant Prostate Cancer Control. Case Reports in Oncology 12:3, pages 688-692.
Crossref
Crossref
C.M. Schooling & Jack C.M. Ng. (2019) Reproduction and longevity A Mendelian randomization study of gonadotropin-releasing hormone and ischemic heart disease. SSM - Population Health, pages 100411.
Crossref
Crossref
R. A. Gafanov, A. G. Dzidzaria, I. B. Kravtsov & S. V. Fastovets. (2019) Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection. Cancer Urology 14:4, pages 139-149.
Crossref
Crossref
Andrew W. HahnCelestia S. HiganoMary-Ellen TaplinCharles J. RyanNeeraj Agarwal. (2018) Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. American Society of Clinical Oncology Educational Book:38, pages 363-371.
Crossref
Crossref
Wojciech Marlicz, Agata Poniewierska-Baran, Sylwia Rzeszotek, Rafał Bartoszewski, Karolina Skonieczna-Żydecka, Teresa Starzyńska & Mariusz Z. Ratajczak. (2018) A novel potential role of pituitary gonadotropins in the pathogenesis of human colorectal cancer. PLOS ONE 13:3, pages e0189337.
Crossref
Crossref
Jin Bong Choi & Jun Sung Koh. 2018. Management of Advanced Prostate Cancer. Management of Advanced Prostate Cancer
127
132
.
Fangxia Zou, Yao Wang, Dawei Yu, Chunjiao Liu, Jing Lu, Min Zhao, Mingxu Ma, Wenyan Wang, Wanglin Jiang, Yonglin Gao, Rui Zhang, Jianzhao Zhang, Liang Ye & Jingwei Tian. (2022) Discovery of the Thieno[2,3-d]Pyrimidine-2,4-Dione Derivative 21a: A Potent and Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist. SSRN Electronic Journal.
Crossref
Crossref